Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subjects ≥18 years of age~* The body mass index is in the range of 18.0-26.0 kg/m2 (including the critical value).~* The weight of male is not less than 50.0 kg, and that of female is not less than 45.0 kg.~* Serum total cholesterol was between 2.9 and 5.0mmol/L (not including critical value).~Exclusion Criteria:~* any medical history of cardiovascular, digestive, respiratory, nervous or ematological diseases~* hepatic/renal impairment~* abnormal vital signs~* drug or alcohol abuse~* smoking ≥5 cigarettes per day ,~* donation(≥300ml) o~* enrollment in other clinical trials during the 3 months prior to screening~* allergic to ezetimibe or its excipients~* any use of other prescription drugs or vitamins or caffeine/xanthine-rich beverages 48h prior to taking medication~* lactating or pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ezetimibe tablet (Type: EXPERIMENTAL): ezetimibe tablet test formulation at a single dose of 10 mg
- ezetimibe tablet(Ezetrol ®) (Type: ACTIVE_COMPARATOR): ezetimibe tablet reference formulation at a single dose of 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).